The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | The role of immunotherapy with KRAS inhibitors in KRAS-driven NSCLC
Jia Luo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the role for immunotherapy in patients with KRAS-driven non-small cell lung cancer (NSCLC). For a patient with advanced KRAS-driven NSCLC, Dr Luo recommends beginning with immunotherapy (IO) due to previously observed benefits of IO in this patient population. The timing of treatment with a KRAS inhibitor has yet to be determined, including which individuals would benefit from KRAS inhibitors in earlier lines of treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Transcript
So, currently, for an individual with a new diagnosis of advanced KRAS mutant non-small cell lung cancer, we would recommend individuals start with immunotherapy based treatments, since there is benefit in KRAS mutant lung cancer. I think in the near future, we’ll have to figure out how to integrate these KRAS inhibitors, when should we do up front? When should we do it later? I think right now, we’re just at the beginning of trying to figure out what sorts of individuals, potentially individuals who have both KRAS and STK11 might benefit from these drugs earlier, and so we’re trying to do a lot of research in the field to tease apart those challenging questions...
So, currently, for an individual with a new diagnosis of advanced KRAS mutant non-small cell lung cancer, we would recommend individuals start with immunotherapy based treatments, since there is benefit in KRAS mutant lung cancer. I think in the near future, we’ll have to figure out how to integrate these KRAS inhibitors, when should we do up front? When should we do it later? I think right now, we’re just at the beginning of trying to figure out what sorts of individuals, potentially individuals who have both KRAS and STK11 might benefit from these drugs earlier, and so we’re trying to do a lot of research in the field to tease apart those challenging questions.
Read more...
